SCHEMBL6838655

SCHEMBL6838655

Nc1ncnc2c1ncc(=O)n2C1OC(CO)C(O)C1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSPA8 P11142 3/20 0.71
▸ HSPA5 P11021 2/20 0.71
▸ ADORA3 P0DMS8 4/20 0.65
▸ GAPDH P04406 3/20 0.65
▸ SMN1; SMN2 Q16637 2/20 0.65
▸ SLC28A2 O43868 2/20 0.65
▸ ADORA2A P29274 2/20 0.65
▸ DPP4 P27487 1/20 0.65
▸ MEN1 O00255 1/20 0.65
▸ SLC28A1 O00337 1/20 0.65
▸ MAP3K7 O43318 1/20 0.65
▸ MAPK1 P28482 1/20 0.65
▸ ADORA2B P29275 1/20 0.65
▸ ADORA1 P30542 1/20 0.65
▸ STAT6 P42226 1/20 0.65
▸ PI4KA P42356 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ PI4K2B Q8TCG2 1/20 0.65
▸ DOT1L Q8TEK3 1/20 0.65
▸ SLC29A1 Q99808 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17412455 0.83 HSPA8 (1.00) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL1145052 0.83 HSPA8 (1.00) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL1145049 0.83 HSPA8 (1.00) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL6840004 0.82 HSPA8 (0.60) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL5362344 0.82 HSPA8 (0.80) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL18858928 0.82 HSPA8 (0.80) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL15906300 0.82 HSPA8 (0.80) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL6305168 0.82 HSPA8 (0.80) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL15906323 0.82 HSPA8 (0.80) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2
SCHEMBL967124 0.82 HSPA8 (0.80) HSPA8HSPA5ADORA3GAPDHSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063658-A1 Nucleoside derivatives for treating hepatitis C virus infection GENELABS TECHNOLOGIES, INC. 2004-04-01 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063658-A1 Nucleoside derivatives for treating hepatitis C virus infection HAVCR2, PNP, NTPCR HSPA8 1928/4885HSPA5 2092/4885ADORA3 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback